Metraipolis › archive › dc_16ef4815ffca

Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy — Europe PMC PMID:40974370

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40974370
DOI: 10.1002/advs.202503979
License (as archived): solo-consultazione
Archived: 2026-11-09T20:28:25.912Z
SHA-256 of the archived text: f2669f85e3d3017d0b5c36202d073b313aa0a65bf6b1f8bec11b9c4d24be8c61
Stable URL of this page: https://metraipolis.com/documento/dc_16ef4815ffca

How to cite

Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy — Europe PMC PMID:40974370 — Europe PMC (en), https://europepmc.org/article/MED/40974370 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_16ef4815ffca (Metraipolis archive dc_16ef4815ffca, sha256 f2669f85e3d3017d0b5c36202d073b313aa0a65bf6b1f8bec11b9c4d24be8c61)

BibTeX

@misc{dc16ef4815ffca,
  title = {Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy — Europe PMC PMID:40974370},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40974370},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_16ef4815ffca; sha256 f2669f85e3d3017d0b5c36202d073b313aa0a65bf6b1f8bec11b9c4d24be8c61},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40974370. Agents can read the archived copy with the MCP tool read_document.